The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
ER-negative /PR-positive breast carcinomas or technical artifacts in immunohistochemistry?
Zahra Maleki; Siamak Shariat; Mehrdad Mokri; Morteza Atri (Profiled Author: Zahra Maleki)
Department of Pathology, The Johns Hopkins Hospital, 600 Wolfe St., Baltimore, MD 21287, USA. firstname.lastname@example.org
Archives of Iranian medicine 2012;15(6):366-9.
BACKGROUND: Evaluation of estrogen (ER) and progesterone (PR) receptors is important in the management and prognosis of breast cancer patients. Immunohistochemistry (IHC) is currently the worldwide accepted methodology for detection of ER/PR receptors in breast carcinomas. However, technical artifacts may alter the results. Since most authorities believe that there are no true ER-negative/PR-positive breast tumors, therefore we hypothesized that technical artifact in IHC might cause ER-negative/PR positive cases. METHODS: The clinical records of 2432 patients treated by surgery at six community hospitals for different histologic subtypes of breast carcinoma were reviewed. Among them, 43 (1.8%) patients reported as ER-negative/PR-positive were re-evaluated in a reference laboratory. Expressions of ER and PR were evaluated by IHC on the same paraffin block used for the initial testing. RESULTS: The repeat study showed that of the 43 patients with the initial results of ER-negative/PR-positive, 24 (55.8%) were ER-positive/PR-positive, 15 (34.9%) were ER-negative/PR-negative, and 4 (9.3%) were ER-positive/PR-negative. In none of the 43 cases were the initial results (ER-negative/PR-positive) confirmed. CONCLUSION: Technical artifacts in IHC may alter ER/PR results in breast carcinomas. The technical factors affecting steroid receptor IHC ought to be properly controlled to provide reliable results.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
M Elizabeth H Hammond; Daniel F Hayes; Mitch Dowsett; D Craig Allred; Karen L Hagerty; Sunil Badve; Patrick L Fitzgibbons; Glenn Francis; Neil S Goldstein; Malcolm Hayes; et al.
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).Archives of pathology & laboratory medicine 2010;134(7):e48-72.
S M de la Monte; G M Hutchins; G W MooreThe American journal of medicine 1984;76(1):11-7.
Paul E Goss; James N Ingle; Silvana Martino; Nicholas J Robert; Hyman B Muss; Martine J Piccart; Monica Castiglione; Dongsheng Tu; Lois E Shepherd; Kathleen I Pritchard; et al.Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(15):2006-11.
Appears in this Publication
Author of this Publication